Á. Palma

2 papers in the library · 2 citations · publishing 2016-2017

Papers

What are sweet dreams made of? Analysis of psychoactive substances into “gummies”: A retrospective descriptive study

European Psychiatry April 1, 2017 Amira Trabsa, E. Monteagudo, D.d. Mariona et al. 2 citations

Among 8324 drug samples submitted to a Spanish harm-reduction organization between 2014 and 2015, nine were gummy formulations—a novel delivery form for psychoactive substances. Analysis by gas chromatography-mass spectrometry showed that 55.5% of these gummies contained multiple drugs. The most common substance was 25N-NBOMe, found in 66.7% of samples; other detected substances included 2C-E, 2C-D, allylescaline, cocaine, THC, ketamine, MDMA, and caffeine. Only 25N-NBOMe was present in an active dosage. Two-thirds of the gummies did not contain the substance the consumer expected, indicating risks of unintended effects.

DOI: 10.1016/j.eurpsy.2017.01.1777 Full text MDMA Ecstasy Psychoactive substance Psychoactive drug +3

25I-NBOMe: The legal LSD

European Psychiatry March 1, 2016 I. Ezquiaga, M. Grifell, L. Galindo et al.

Between 2009 and 2015, 56 samples of the potent hallucinogen 25I-NBOMe were identified among 21,198 drug samples submitted to a Spanish harm-reduction service. Most samples (42.8%) were sold as LSD, while only 21.4% were sold as 25I-NBOMe itself; others were misrepresented as related substances or even gummy bears. All 25I-NBOMe samples appeared after 2012, with a peak in 2013. The substance has high affinity for serotonin 5HT2a receptors and has been linked to toxicity. The authors call for more research and for physicians to be aware of novel psychoactive substances and their clinical differences.

DOI: 10.1016/j.eurpsy.2016.01.006